NCT03485274 is a Phase 2, PHASE3 clinical trial of Vortioxetine in Cannabis Use Disorder, sponsored by The University of Hong Kong.

Who is sponsoring NCT03485274?

NCT03485274 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT03485274?

Interventions in NCT03485274: Vortioxetine, Treatment as Usual.

What condition does NCT03485274 study?

NCT03485274 studies Cannabis Use Disorder, Depressive State, Anxiety State, Depression, Anxiety Disorders, Pharmacotherapy.

Is NCT03485274 still recruiting?

NCT03485274 is currently completed. Last updated 5 July 2023.

Last reviewed 2023-07-05 · How we verify

NCT03485274

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Substance Misuse To Psychiatric Disorders for Cannabis

Completed Phase 2, PHASE3 Last updated 5 July 2023

What this trial tests

Phase 2, PHASE3 trial testing Vortioxetine in Cannabis Use Disorder in 37 participants. Completed in 30 April 2023.

Timeline

25 July 2018

Primary endpoint
28 February 2023

30 April 2023

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	37
Start date	25 July 2018
Primary completion	28 February 2023
Estimated completion	30 April 2023
Sites	1 location across Hong Kong

Drugs / interventions tested

Vortioxetine (vortioxetine) — full drug profile →
Treatment as Usual

Conditions studied

Cannabis Use Disorder — all drugs for Cannabis Use Disorder →
Depressive State — all drugs for Depressive State →
Anxiety State — all drugs for Anxiety State →
Depression — all drugs for Depression →

Sponsor

The University of Hong Kong

Who can join

Adults 16 to 50, any sex, with Cannabis Use Disorder or Depressive State. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Determining the diagnostic cut-off on the Chinese version of severity of dependence scale for DSM-5 stimulant use disorder.
Chung AKK, Leung W, Tse CY. · · 2025 · PMID 40980032 · DOI 10.3389/fpsyt.2025.1622306

Verify or expand the search:

Other trials of Vortioxetine

Trials testing the same drug.

NCT07266545 — RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) · Phase 4 · recruiting
NCT06604520 — Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia · Phase 2 · recruiting
NCT05814640 — Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) · Phase 1, PHASE2 · recruiting
NCT04446039 — Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea · completed
NCT05481957 — Vortioxetine Adjunctive Treatment in Bipolar Depression · Phase 4 · completed

Other recruiting trials for Cannabis Use Disorder

Currently open trials in the same condition.

NCT07523633 — Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
NCT07218471 — Cannabis Reduction and Functional Outcomes · NA · recruiting
NCT07184983 — RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative · NA · recruiting
NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03485274 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 5 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03485274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing